Crinetics Pharmaceuticals (CRNX) Cash from Investing Activities (2017 - 2026)

Crinetics Pharmaceuticals' Cash from Investing Activities history runs 10 years deep, the most recent figure standing at -$252.4 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 193.57% year-over-year to -$252.4 million in Q1 2026; TTM through Mar 2026 was $7.5 million, a 101.14% increase from a year earlier, with the FY2025 full-year figure at $173.9 million, up 130.25% from the prior year.
• Cash from Investing Activities declined to -$252.4 million in Q1 2026 per CRNX's latest filing, from $57.1 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $164.8 million in Q3 2025 and bottomed at -$542.1 million in Q4 2024.
• The 5-year median for Cash from Investing Activities is $309000.0 (2024), against an average of -$60.5 million.
• Biggest YoY gain for Cash from Investing Activities was 699.93% in 2025; the steepest drop was 27919.09% in 2025.
• Year by year, Cash from Investing Activities stood at $36.9 million in 2022, then sank by 336.91% to -$87.3 million in 2023, then slumped by 520.89% to -$542.1 million in 2024, then surged by 110.53% to $57.1 million in 2025, then sank by 541.91% to -$252.4 million in 2026.
• Per Business Quant, the three latest CRNX Cash from Investing Activities figures stand at -$252.4 million (Q1 2026), $57.1 million (Q4 2025), and $164.8 million (Q3 2025).